Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Aug;96(8):1136-43.
doi: 10.3324/haematol.2010.038109. Epub 2011 May 5.

Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA

Olivier Fitoussi  1 , Karim Belhadj, Nicolas Mounier, Marie Parrens, Hervé Tilly, Gilles Salles, Pierre Feugier, Christophe Ferme, Loic Ysebaert, Jean Gabarre, Raoul Herbrecht, Maud Janvier, Eric Van Den Neste, Franck Morschhauser, Olivier Casasnovas, Hervé Ghesquieres, Bruno Anglaret, Sabine Brechignac, Corinne Haioun, Christian Gisselbrecht
Affiliations
Clinical Trial

Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA

Olivier Fitoussi et al. Haematologica. 2011 Aug.

Abstract

Background: As rituximab combined with CHOP improves complete remission and overall survival in diffuse large B-cell lymphoma, intensified chemotherapy followed by autologous stem-cell transplantation has also been advocated for high-risk patients. The aim of this study was to establish whether or not combining rituximab with high-dose chemotherapy and auto-transplantation also benefits patient survival.

Design and methods: The LNH2003-3 study was a phase II trial including diffuse large B-cell lymphoma patients with 2 or 3 International Prognostic Index factors. They received four cycles of intensive biweekly chemotherapy with rituximab, doxorubicine, cyclophosphamide, vindesine, bleomycine, prednisolone (R-ACVBP) followed by auto-transplantation in responding patients. Two hundred and nine patients under 60 years of age were included in the study and 155 responding patients underwent auto-transplantation. In addition, a case-control study was performed by matching (1:1) 181 patients treated with R-ACVBP with ACVBP patients not given rituximab but submitted to auto-transplantation from the previous LNH1998-3 trial.

Results: With a median follow up of 45 months, 4-year progression-free survival and overall survival were estimated at 76% (CI: 69-81) and 78% (CI: 72-83), respectively. There was no difference between patients with 2 or 3 International Prognostic Index factors. Four year progression-free survival was significantly higher in R-ACVBP than ACVBP patients (74% vs. 58%; P=0.0005). There was also a significant increase in 4-year overall survival (76% vs. 68%; P=0.0494).

Conclusions: In high-risk diffuse large B-cell lymphoma patients, treatment with R-ACVBP followed by auto-transplantation results in a 78% 4-year overall survival which should be compared to other approaches.

Trial registration: ClinicalTrials.gov NCT00144807.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
PFS (A) and OS (B) according to the age-adjusted International Prognostic Index (aa-IPI).
Figure 2.
Figure 2.
OS for R-ACVBP vs. ACVBP. (A) Whole population. (B) Patients given ASCT.
See this image and copyright information in PMC

References

    1. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–61. - PubMed
    1. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987–94. - PubMed
    1. Arranz R, Conde E, Grande C, Mateos MV, Gandarillas M, Albo C, et al. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group. Eur J Haematol. 2008;80(3):227–35. - PubMed
    1. Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med. 1997;336(18):1290–7. - PubMed
    1. Glass B, Kloess M, Bentz M, Schlimok G, Berdel WE, Feller A, et al. Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma. Blood. 2006;107(8):3058–64. - PubMed

Publication types

MeSH terms

Supplementary concepts

Associated data